CG Oncology said it will present clinical updates on cretostimogene at the SCSAUA Annual Meeting this week, with oral presentations set for Friday. The update comes as the company advances its Phase 3 BOND-003 trial in high-risk NMIBC carcinoma in situ.
published
CG Oncology said it will present clinical updates on cretostimogene at the SCSAUA Annual Meeting this week, with oral presentations set for Friday. The update comes as the company advances its Phase 3 BOND-003 trial in high-risk NMIBC carcinoma in situ.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.